Cargando…

Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases

BACKGROUND/AIMS: To investigate the long-term outcomes of cultivated oral mucosal epithelial transplantation (COMET) for fornix reconstruction in eyes with chronic cicatrising disease. METHODS: This retrospective cohort study involved 16 eyes of 15 patients who underwent COMET for symblepharon relea...

Descripción completa

Detalles Bibliográficos
Autores principales: Komai, Seitaro, Inatomi, Tsutomu, Nakamura, Takahiro, Ueta, Mayumi, Horiguchi, Go, Teramukai, Satoshi, Kimura, Yasuko, Kagimura, Tatsuo, Fukushima, Masanori, Kinoshita, Shigeru, Sotozono, Chie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510423/
https://www.ncbi.nlm.nih.gov/pubmed/34006509
http://dx.doi.org/10.1136/bjophthalmol-2020-318547
_version_ 1784797437755392000
author Komai, Seitaro
Inatomi, Tsutomu
Nakamura, Takahiro
Ueta, Mayumi
Horiguchi, Go
Teramukai, Satoshi
Kimura, Yasuko
Kagimura, Tatsuo
Fukushima, Masanori
Kinoshita, Shigeru
Sotozono, Chie
author_facet Komai, Seitaro
Inatomi, Tsutomu
Nakamura, Takahiro
Ueta, Mayumi
Horiguchi, Go
Teramukai, Satoshi
Kimura, Yasuko
Kagimura, Tatsuo
Fukushima, Masanori
Kinoshita, Shigeru
Sotozono, Chie
author_sort Komai, Seitaro
collection PubMed
description BACKGROUND/AIMS: To investigate the long-term outcomes of cultivated oral mucosal epithelial transplantation (COMET) for fornix reconstruction in eyes with chronic cicatrising disease. METHODS: This retrospective cohort study involved 16 eyes of 15 patients who underwent COMET for symblepharon release and fornix reconstruction between June 2002 and December 2008. The mean postoperative follow-up period was 102.1±46.0 months (range: 32–183 months). The treated cicatrising disorders included ocular cicatricial pemphigoid (OCP, five eyes), thermal/chemical injury (three eyes) and other chronic diseases (seven eyes; including recurrent pterygium (two eyes), Stevens-Johnson syndrome (one eye) and graft-versus-host disease (one eye)). Ocular-surface appearance was evaluated before surgery, at 1, 4, 12 and 24 weeks postoperative, and then annually based on the previously reported scoring system. Main outcome measures included overall and disease-specific fornix-reconstruction success probabilities analysed by the Kaplan-Meier survival curve. Symblepharon/fornix-shortening recurrence at 24 weeks postoperative, and its relationship to long-term surgical success was also examined. RESULTS: At 5 years postoperative, the mean±SD overall fornix-reconstruction success probability was 79.6%±10.7%, and success probability for thermal/chemical injury and OCP was 100% and 53.3%±24.8%, respectively (p=0.53, log-rank test). The 3-year success probability was significantly higher in the no-disease-recurrence group at 24 weeks postoperative (13 eyes) than in the disease-recurrence group (three eyes) (100% and 33.3%±27.2%, respectively) (p=0.0073, log-rank test). CONCLUSION: COMET was found to be safe and effective for symblepharon release and long-term fornix reconstruction in eyes with chronic cicatrisation. Although the 5-year success probability differed depend on the underlying disease, ocular-surface appearance at 24 weeks postoperative is a factor for predicting long-term outcome.
format Online
Article
Text
id pubmed-9510423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95104232022-09-27 Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases Komai, Seitaro Inatomi, Tsutomu Nakamura, Takahiro Ueta, Mayumi Horiguchi, Go Teramukai, Satoshi Kimura, Yasuko Kagimura, Tatsuo Fukushima, Masanori Kinoshita, Shigeru Sotozono, Chie Br J Ophthalmol Clinical Science BACKGROUND/AIMS: To investigate the long-term outcomes of cultivated oral mucosal epithelial transplantation (COMET) for fornix reconstruction in eyes with chronic cicatrising disease. METHODS: This retrospective cohort study involved 16 eyes of 15 patients who underwent COMET for symblepharon release and fornix reconstruction between June 2002 and December 2008. The mean postoperative follow-up period was 102.1±46.0 months (range: 32–183 months). The treated cicatrising disorders included ocular cicatricial pemphigoid (OCP, five eyes), thermal/chemical injury (three eyes) and other chronic diseases (seven eyes; including recurrent pterygium (two eyes), Stevens-Johnson syndrome (one eye) and graft-versus-host disease (one eye)). Ocular-surface appearance was evaluated before surgery, at 1, 4, 12 and 24 weeks postoperative, and then annually based on the previously reported scoring system. Main outcome measures included overall and disease-specific fornix-reconstruction success probabilities analysed by the Kaplan-Meier survival curve. Symblepharon/fornix-shortening recurrence at 24 weeks postoperative, and its relationship to long-term surgical success was also examined. RESULTS: At 5 years postoperative, the mean±SD overall fornix-reconstruction success probability was 79.6%±10.7%, and success probability for thermal/chemical injury and OCP was 100% and 53.3%±24.8%, respectively (p=0.53, log-rank test). The 3-year success probability was significantly higher in the no-disease-recurrence group at 24 weeks postoperative (13 eyes) than in the disease-recurrence group (three eyes) (100% and 33.3%±27.2%, respectively) (p=0.0073, log-rank test). CONCLUSION: COMET was found to be safe and effective for symblepharon release and long-term fornix reconstruction in eyes with chronic cicatrisation. Although the 5-year success probability differed depend on the underlying disease, ocular-surface appearance at 24 weeks postoperative is a factor for predicting long-term outcome. BMJ Publishing Group 2022-10 2021-05-18 /pmc/articles/PMC9510423/ /pubmed/34006509 http://dx.doi.org/10.1136/bjophthalmol-2020-318547 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical Science
Komai, Seitaro
Inatomi, Tsutomu
Nakamura, Takahiro
Ueta, Mayumi
Horiguchi, Go
Teramukai, Satoshi
Kimura, Yasuko
Kagimura, Tatsuo
Fukushima, Masanori
Kinoshita, Shigeru
Sotozono, Chie
Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title_full Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title_fullStr Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title_full_unstemmed Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title_short Long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
title_sort long-term outcome of cultivated oral mucosal epithelial transplantation for fornix reconstruction in chronic cicatrising diseases
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510423/
https://www.ncbi.nlm.nih.gov/pubmed/34006509
http://dx.doi.org/10.1136/bjophthalmol-2020-318547
work_keys_str_mv AT komaiseitaro longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT inatomitsutomu longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT nakamuratakahiro longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT uetamayumi longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT horiguchigo longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT teramukaisatoshi longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT kimurayasuko longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT kagimuratatsuo longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT fukushimamasanori longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT kinoshitashigeru longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases
AT sotozonochie longtermoutcomeofcultivatedoralmucosalepithelialtransplantationforfornixreconstructioninchroniccicatrisingdiseases